Molecular relapse occurred later in patients with RUNX1::RUNX1T1 AML (median of 377 days [269–452] vs. 269 [199–371] vs. 279 [233–371]) while morphologic relapse occurred earlier in these patients (median of 288 [170–570] vs. 337 [305–456] vs. 355 [245–527]). The gene discussed is RUNX1; the disease is acute myeloid leukemia.